Related Experiment Video
Updated: May 18, 2026
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MUC1 immunotherapy is here to stay
Takashi Kimura1, Olivera J Finn
1University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA 15261 , USA.
Introduction:
Success of HBV vaccines in reducing the incidence of liver cancer, and HPV vaccines in reducing preneoplastic cervical lesions, demonstrate the potential of cancer reduction by harnessing the immune system. For most human cancers, infectious etiology is not known but other tumor antigens, candidates for vaccines, have been identified.
Areas Covered:
The authors discuss knowledge accumulated the last two decades on the tumor antigen MUC1 that has put it at the top of the list as an immunotherapy reagent. They examine evidence that anti-MUC1 immunity affects tumor development and prognosis. Finally, they review two decades of immunotherapy trials targeting MUC1, focusing primarily on vaccines but also adoptive antibody and T-cell therapies.
Expert Opinion:
Most approaches targeting MUC1 have been immunotherapies administered to date to more than 1200 patients in clinical trials. Even though these trials focused on advanced cancer, encouraging results were reported particularly for less immunosuppressed patients. Furthermore, spontaneous anti-MUC1 immune responses are associated with better prognosis or with a reduced lifetime risk of developing MUC1+ cancers. MUC1 is abnormally expressed in over 80% of all cancers. Successfully targeting this molecule could benefit over a million patients diagnosed yearly with MUC1+ tumors just in the USA.
Insights
Cancer vaccines harnessing the immune system show promise. Targeting the MUC1 tumor antigen, a key immunotherapy target, has shown encouraging results in clinical trials for advanced cancers.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Vaccine success in reducing cancer incidence (HBV, HPV) highlights immune system potential.
- While infectious causes are unknown for most cancers, tumor antigens are identified as vaccine targets.
Purpose of the Study:
- To review two decades of research on the MUC1 tumor antigen as an immunotherapy reagent.
- To examine the impact of anti-MUC1 immunity on tumor development and prognosis.
- To analyze immunotherapy trials targeting MUC1, including vaccines, antibody, and T-cell therapies.
Main Methods:
- Review of accumulated knowledge on MUC1 over two decades.
- Examination of evidence linking anti-MUC1 immunity to tumor progression and patient outcomes.
- Analysis of clinical trial data from immunotherapies targeting MUC1.
Main Results:
- Over 1200 patients have participated in MUC1-targeted immunotherapy trials.
- Encouraging results observed, especially in less immunosuppressed patients with advanced cancer.
- Spontaneous anti-MUC1 immune responses correlate with better prognosis and reduced cancer risk.
Conclusions:
- MUC1 is abnormally expressed in over 80% of human cancers, making it a significant therapeutic target.
- Targeting MUC1 immunotherapy could potentially benefit over a million patients annually in the USA.
- Further research into MUC1-targeted immunotherapies holds significant promise for cancer treatment.
Related Concept Videos
01:27Tumor Immunotherapy
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:25Mucosal Barrier of the Stomach
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
01:29Microorganisms in Medicine and Therapeutics
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...